Multi-layer tumor-activated nanoliposomal mRNA platform with glutathione-responsive disulfide or reactive oxygen species-sensitive release and mirna-mediated tissue exclusion for selective induction of apoptosis

A multi-layer nanoliposomal mRNA delivery system with tumor-targeting, stimulus-responsive release, and miRNA-mediated exclusion addresses the lack of selectivity in conventional LNPs, achieving precise tumor apoptosis with reduced off-target toxicity.

WO2026239200A1PCT designated stage Publication Date: 2026-11-19ADAM EMAN HUSSEIN MOHAMED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/054371
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-10
Filing Date
2026-05-03
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Conventional lipid nanoparticles (LNPs) lack tumor-intrinsic selectivity, leading to off-target expression and safety concerns in non-neoplastic tissues, while existing platforms fail to integrate receptor-mediated targeting, stimulus-responsive intracellular release, and miRNA-mediated tissue exclusion for mRNA delivery.

Method used

A multi-layer nanoliposomal mRNA delivery system with tumor-targeting ligands, glutathione- or reactive oxygen species-sensitive release mechanisms, and miRNA-responsive elements to achieve selective apoptosis in tumor cells, incorporating a bicistronic mRNA encoding tBID and BAX with miRNA-mediated suppression in normal tissues.

Benefits of technology

The system ensures high precision and safety by preferentially targeting tumor cells, triggering mRNA release only in malignant environments, and suppressing translation in normal tissues, reducing off-target toxicity and enhancing therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure 00000008_0000
    Figure 00000008_0000
  • Figure 00000009_0000
    Figure 00000009_0000
Patent Text Reader

Abstract

Disclosed herein is a multi-layer tumor-activated nanoliposomal mRNA delivery platform for selective induction of apoptosis in cancer cells. The system integrates three orthogonal selectivity mechanisms: (1) surface-displayed tumor-targeting ligands (glucose moieties exploiting GLUT1 / GLUT3 overexpression) for receptor-mediated preferential cellular uptake; (2) stimulus-sensitive linkers responsive to elevated intracellular glutathione (disulfide bond) or reactive oxygen species (thioketal or arylboronate), enabling tumor-specific mRNA payload release; and (3) miRNA-responsive elements (MREs) in the 3' untranslated region suppressing translation in normal tissues, providing post-transcriptional tissue exclusion. The encapsulated mRNA encodes a bicistronic pro-apoptotic construct: 5'Cap — 5'UTR — tBID — P2A — BAX — 3'UTR(MREs) — Poly(A). Ribosomal skipping at the P2A peptide enables co-expression of truncated BID and BAX, mediating mitochondrial outer membrane permeabilization and caspase activation. Alternative payloads including granzyme B are encompassed. The platform provides superior tumor selectivity, reduced systemic toxicity, and modular adaptability to diverse oncological indications.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DESCRIPTION

[0002] TITLE OF INVENTION MULTI-LAYER TUMOR-ACTIVATED NANOLIPOSOMAL mRNA PLATFORM WITH GLUTATHIONE-RESPONSIVE DISULFIDE OR REACTIVE OXYGEN SPECIES-SENSITIVE RELEASE AND miRNA-MEDIATED TISSUE EXCLUSION FOR SELECTIVE INDUCTION OF APOPTOSIS TECHNICAL FIELD

[0003] The present invention relates to the field of oncology and nanomedicine. More specifically, it relates to a multi-functional nanoliposomal delivery system for messenger RNA (mRNA) therapeutics engineered to selectively induce apoptosis in tumor cells through a combination of receptor-mediated targeting, stimulus-responsive intracellular release, and microRNA (miRNA)-mediated post-transcriptional tissue exclusion.

[0004] BACKGROUND OF THE D ENTON

[0005] Cancer remains one of the most significant global health challenges, with conventional therapeutic modalities — including chemotherapy, radiation, and surgery — suffering from limited specificity, systemic toxicity, and multidrug resistance. The emergence of nucleic acid therapeutics, particularly mRNA-based approaches, has opened transformative opportunities for selective cancer treatment. However, efficient and tumor-specific delivery of mRNA in vivo remains a critical unmet need.

[0006] Lipid nanoparticles (LNPs) have demonstrated considerable clinical utility as delivery vehicles for nucleic acids, as evidenced by approved mRNA vaccines and siRNA therapeutics. Nevertheless, conventional LNPs lack tumor-intrinsic selectivity at the molecular level, resulting in off-target expression in non-neoplastic tissues such as the liver and spleen. This limitation undermines therapeutic efficacy and raises safety concerns for apoptosis-inducing payloads.

[0007] Tumor microenvironments exhibit distinct biochemical hallmarks that can be exploited for stimulus-responsive drug release. In particular, intracellular glutathione (GSH) concentrations are reported to be approximately 100- to 1000-fold higher in cancer cells relative to extracellular spaces, while reactive oxygen species (ROS) levels are also characteristically elevated in malignant cells. These features make GSH-sensitive disulfide bonds and ROS-sensitive chemical moieties attractive triggers for intracellular payload release.

[0008] Furthermore, differential expression of microRNAs (miRNAs) between tumor and normal tissues provides a second layer of post-transcriptional regulatory control. Incorporation of miRNA-responsive elements (MREs) into the 3' untranslated region (3'UTR) of therapeutic mRNA enables translational suppression in non-target cell types that express the corresponding miRNA, further enhancing selectivity.Pro-apoptotic proteins of the BCL-2 family, particularly truncated BID (tBID) and BAX, are established mediators of the intrinsic mitochondrial apoptosis pathway. Coordinated expression of tBID and BAX induces cytochrome c release and downstream caspase activation, representing a potent and direct apoptotic signal. Delivery of mRNA encoding such constructs offers transient, non-integrating expression with reduced immunogenicity compared to viral vectors.

[0009] Despite individual advances in each of these areas, no existing platform integrates receptor- mediated tumor targeting, stimulus-responsive intracellular mRNA release, and miRNA-mediated tissue exclusion into a unified nanoliposomal mRNA delivery system. The present invention addresses this gap by providing a multi-layer selectivity architecture that achieves tumor-cell-specific apoptosis induction with high precision and safety.

[0010] SUMMARY OF THE INVENTION

[0011] The present invention provides a multi-layer tumor-activated nanoliposomal mRNA delivery platform comprising: (i) a lipid-based nanoparticle functionalized with tumor-targeting ligands for enhanced cellular uptake; (ii) a stimulus-sensitive release mechanism responsive to intracellular glutathione (GSH) or reactive oxygen species (ROS); (iii) an mRNA construct encoding dual pro-apoptotic proteins tBID and BAX separated by a self-cleaving P2A peptide sequence; and (iv) miRNA-responsive elements incorporated into the 3'UTR of the mRNA to suppress translation in non-target tissues expressing defined miRNAs.

[0012] This invention achieves selective tumor cell killing through three orthogonal and synergistic layers of selectivity: (1) preferential uptake by tumor cells via surface-conjugated targeting ligands that exploit overexpressed receptors; (2) intracellular triggered release of mRNA payload upon encountering elevated GSH or ROS concentrations exclusive to malignant cells; and (3) miRNA-mediated post-transcriptional silencing in normal tissues.

[0013] The platform further encompasses alternative apoptotic payload configurations, including mRNA encoding cytotoxic proteases such as granzyme B, and may be adapted for single or combination payload delivery. The invention provides significant therapeutic advantages over existing approaches, including reduced off-target toxicity, transient and non-integrating gene expression, scalable lipid nanoparticle manufacturing, and modular design accommodating diverse tumor indications.

[0014] BRIEF DESCRIPTION OF THE INVENTION

[0015]

[0016] The nanoliposomal carrier of the present invention is a lipid-based nanoparticle comprising an ionizable or cationic lipid component, a helper lipid (e.g., DSPC or DOPE), cholesterol, and a PEGylated lipid, formulated to encapsulate mRNA cargo and protect it from nuclease degradation. The particle size is preferably in the range of 80-200 nm to facilitate tumor accumulation via the enhanced permeability and retention (EPR) effect.The surface of the nanoliposome is functionalized with one or more tumor-targeting ligands. In preferred embodiments, glucose moieties are conjugated to the particle surface to exploit overexpression of glucose transporter proteins (e.g., GLUT1, GLUT3) characteristic of highly glycolytic tumor cells. In alternative embodiments, the targeting ligand comprises folate, transferrin, aptamers, or antibody fragments directed against tumor-associated antigens, including but not limited to HER2, EGFR, or PD-L1.

[0017] 2. Stimulus-Sensitive Release Mechanism

[0018] A. Glutathione-Sensitive Embodiment (Primary)

[0019] In the primary embodiment, the nanoliposomal carrier incorporates a glutathione-responsive disulfide-containing linker that tethers the mRNA payload or modulates membrane integrity. Intracellular GSH concentrations of 1-10 mM, markedly elevated relative to extracellular concentrations of approximately 2-20 |iM, cleave disulfide bonds upon endosomal escape, triggering release of the mRNA payload into the cytosol. The disulfide bond is stable under extracellular oxidizing conditions, minimizing premature release during circulation.

[0020] B. Reactive Oxygen Species-Sensitive Embodiment (Alternative)

[0021] In the alternative embodiment, the stimulus-sensitive linker incorporates a ROS-labile chemical moiety, such as a thioketal, arylboronate ester, or selenium-containing group, that undergoes selective cleavage in the presence of elevated intracellular hydrogen peroxide (HBOB) or superoxide anion concentrations found in cancer cells. This embodiment provides an orthogonal trigger for mRNA release and may be employed independently or in combination with the disulfide-based approach for dual-stimulus responsiveness.

[0022] 3. mRNA Pavloed Architecture

[0023] The therapeutic mRNA molecule of the present invention encodes a bicistronic construct arranged in a linear, non-overlapping configuration. The mRNA comprises the following structural elements in 5' to 3' orientation:

[0024] • 5' Cap Structure: A modified cap analog (e.g., CleanCap® or ARCA) to enhance translational efficiency and mRNA stability

[0025] • 5' Untranslated Region (5'UTR): An optimized UTR sequence incorporating Kozak consensus elements to maximize ribosome recruitment

[0026] • Coding Sequence 1 — tBID: The open reading frame encoding truncated BID (tBID), a pro-apoptotic BH3-only protein that activates BAX and BAK upon cleavage by caspase-8 or granzyme B, thereby initiating mitochondrial outer membrane permeabilization

[0027] • Self-Cleaving Peptide Linker — P2A: A Thosea asigna virus 2A (T2A or P2A) sequence enabling stoichiometric co-translation of tBID and BAX from a single open reading frame through ribosomal skipping, without requiring separate promoters or IRES elements• Coding Sequence 2 — BAX: The open reading frame encoding BAX (BCL-2-associated X protein), a pore-forming pro-apoptotic effector that, upon activation by tBID, oligomerizes and inserts into the mitochondrial outer membrane to release cytochrome c and trigger the caspase cascade

[0028] • 3' Untranslated Region (3'UTR) with miRNA-Responsive Elements: The 3'UTR contains one or more miRNA-responsive elements (MREs) perfectly or near-perfectly complementary to miRNAs expressed at high levels in normal non-target tissues (e.g., miR-122 for liver, miR-192 for kidney). In cells expressing these miRNAs, RISC-mediated translational repression and / or mRNA degradation occurs, preventing apoptosis induction in normal tissues

[0029] • Poly(A) Tail: A synthetic poly(A) tail of approximately 100-150 adenosine residues to promote mRNA stability and translational efficiency

[0030] 5' Cap — 5 UTR — [tBID] — P2A — [BAX] — 3 UTR (miRNA-Responsive Elements) — Poly(A) 3

[0031] 4. I u8tl-Layer Selectivity Architecture

[0032] The invention achieves tumor selectivity through three integrated and orthogonal mechanisms that collectively minimize off-target expression in normal tissues:

[0033] Layer 1 — Receptor-Mediated Preferential Uptake: Surface targeting ligands (e.g., glucose moieties) exploit tumor-specific receptor overexpression to bias nanoparticle internalization toward malignant cells, reducing systemic distribution to non-target tissues.

[0034] Layer 2 — Stimulus-Responsive Intracellular Activation: GSH- or ROS-sensitive linkers ensure mRNA payload release is triggered specifically within the reducing or oxidative intracellular environment of tumor cells, preventing premature translation extracellularly or in endosomes of normal cells.

[0035] Layer 3 — miRNA-Mediated Post-Transcriptional Tissue Exclusion: MREs within the 3'UTR direct translational suppression of the apoptotic mRNA in normal tissues expressing cognate miRNAs, providing a genomic-level fail-safe against inadvertent apoptosis in healthy cells that may have taken up nanoparticles through non-specific means.

[0036] 5, Alternative and Combination Payload Embodiments

[0037] The modular design of the nanoliposomal platform accommodates alternative mRNA payload configurations. In one alternative embodiment, the mRNA encodes granzyme B, a serine protease that directly activates the apoptotic cascade without requiring upstream BCL-2 family regulation, providing a complementary mechanism of tumor cell killing. In additional embodiments, the platform may co-deliver two or more distinct mRNA molecules targeting independent apoptotic pathways to overcome tumor resistance mechanisms.

Claims

CLAMSWhat is claimed is:

1. A nanoliposomal composition for tumor-selective mRNA delivery, comprising: (a) a lipid-based nanoparticle comprising an ionizable or cationic lipid, a phospholipid helper lipid, cholesterol, and a polyethylene glycol (PEG)-conjugated lipid;(b) at least one tumor-targeting ligand conjugated to the surface of the nanoparticle, wherein the tumor-targeting ligand preferentially binds to a receptor overexpressed on tumor cells;(c) a stimulus-sensitive linker that is cleaved in response to an intracellular stimulus selected from elevated glutathione concentration, elevated reactive oxygen species concentration, or a combination thereof; and(d) a therapeutic mRNA molecule encapsulated within the nanoparticle, wherein the mRNA encodes a pro-apoptotic construct comprising truncated BID (tBID) and BAX separated by a self-cleaving peptide sequence, and wherein the mRNA comprises at least one miRNA-responsive element (MRE) in the 3' untranslated region (3'UTR) configured to suppress translation in non-target cells.

2. The nanoliposomal composition of claim 1, wherein the stimulus-sensitive linker comprises a glutathione-responsive disulfide bond that is stable under extracellular oxidizing conditions and undergoes reductive cleavage upon exposure to intracellular glutathione at concentrations of 1 mM or greater.

3. The nanoliposomal composition of claim 1, wherein the stimulus-sensitive linker comprises a reactive oxygen species-sensitive moiety selected from a thioketal group, an arylboronate ester, a selenium-containing moiety, or combinations thereof, that undergoes cleavage upon exposure to intracellular hydrogen peroxide or superoxide.

4. The nanoliposomal composition of claim 1, wherein the tumor-targeting ligand is a glucose moiety that binds to a glucose transporter protein overexpressed on tumor cells selected from GLUT1, GLUT3, or a combination thereof.

5. The nanoliposomal composition of claim 1, wherein the tumor-targeting ligand is selected from folate, transferrin, an aptamer, a single-chain antibody fragment (scFv), or a peptide ligand directed against a tumor-associated antigen selected from HER2, EGFR, or PD-L1.

6. The nanoliposomal composition of claim 1, wherein the self-cleaving peptide sequence is a 2A peptide selected from P2A derived from Thosea asigna virus 2A, T2A derived from Thosea asigna virus, E2A derived from equine rhinitis A virus, or F2A derived from foot-and-mouth disease virus.

7. The nanoliposomal composition of claim 1, wherein the at least one miRNA-responsive element is complementary to a miRNA selected from miR-122,miR-192, miR-21, miR-126, mi R- 199a, or combinations thereof, wherein said miRNA is expressed at high levels in non-target normal tissues and at low levels in the target tumor tissue.

8. The nanoliposomal composition of claim 1, wherein the mRNA molecule further comprises: a 5' cap structure; an optimized 5' untranslated region comprising Kozak consensus elements; and a synthetic poly(A) tail of 80 to 200 adenosine residues.

9. The nanoliposomal composition of claim 1, wherein the nanoparticle has a mean hydrodynamic diameter of 80 to 200 nanometers as measured by dynamic light scattering.

10. The nanoliposomal composition of claim 1, wherein the stimulus-sensitive linker comprises both a glutathione-responsive disulfide bond and a reactive oxygen species-sensitive moiety, providing dual-stimulus responsiveness.

11. The nanoliposomal composition of claim 1, wherein the therapeutic mRNA molecule further encodes a cytotoxic protease selected from granzyme B, as an alternative or additional pro-apoptotic payload.

12. A method for selectively inducing apoptosis in tumor cells, comprising administering to a subject in need thereof a therapeutically effective amount of the nanoliposomal composition of claim 1, wherein: (a) the tumor-targeting ligand mediates preferential uptake of the nanoparticle by tumor cells; (b) elevated intracellular glutathione or reactive oxygen species within tumor cells cleave the stimulus-sensitive linker to release the therapeutic mRNA; and (c) miRNA-responsive elements in the 3'UTR suppress translation of the apoptotic construct in non-target cells expressing cognate miRNAs.

13. The method of claim 12, wherein the tumor cells are selected from breast cancer, lung cancer, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, ovarian cancer, glioblastoma, or hematological malignancies.

14. A pharmaceutical composition comprising the nanoliposomal composition of claim 1 and a pharmaceutically acceptable carrier, diluent, or excipient, formulated for intravenous, intratumoral, intraperitoneal, or subcutaneous administration.

15. A kit for tumor-selective mRNA therapeutic delivery comprising the nanoliposomal composition of claim 1, instructions for use, and optionally one or more of: a pharmaceutically acceptable diluent; a buffering agent; and one or more companion diagnostics for determining miRNA expression profiles in target and non-target tissues.

16. A multi-layer tumor-selective gene expression system comprising: (i) a first selectivity layer comprising receptor-mediated preferential uptake of a nanoliposomal carrier by tumor cells expressing an overexpressed surface receptor; (ii) a second selectivity layer comprising intracellular stimulus-responsive release of an encapsulated mRNA payload triggered by elevated glutathione or reactive oxygen species concentrations in tumor cells; and (ill) a third selectivitylayer comprising miRNA-mediated post-transcriptional suppression of translation of the mRNA payload in non-target cells expressing cognate miRNA sequences, wherein the combination of all three layers provides synergistic tumor selectivity.

17. The multi-layer tumor-selective gene expression system of claim 16, wherein the mRNA payload encodes a bicistronic construct comprising tBID-P2A-BAX arranged in 5' to 3' orientation, whereby co-translation of tBID and BAX from a single mRNA transcript is achieved via ribosomal skipping at the P2A peptide sequence, enabling coordinated activation of the mitochondrial apoptosis pathway.